CO6341474A2 - Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso - Google Patents
Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su usoInfo
- Publication number
- CO6341474A2 CO6341474A2 CO11004598A CO11004598A CO6341474A2 CO 6341474 A2 CO6341474 A2 CO 6341474A2 CO 11004598 A CO11004598 A CO 11004598A CO 11004598 A CO11004598 A CO 11004598A CO 6341474 A2 CO6341474 A2 CO 6341474A2
- Authority
- CO
- Colombia
- Prior art keywords
- tetraol
- imidazol
- butane
- solid forms
- isoxazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención se relaciona con formas sólidas de (1R, 2S, 3R)-1-(2- (isoxasol-3-iI)-1H-imidazol-4-il) butano- 1, 2, 3, 4-tetraol e hidratos del mismo. Composiciones farmacéuticas que comprenden las formas sólidas de (1R, 2S, 3R)-1-(2-(isoxasol-3-iI)-1H-imidazol-4-il) butano-1, 2, 3, 4-tetraol, que abarca hidratos cristalinos de (1R, 2S, 3R)-1-(2-(isoxasol-3-il)-1H-imidazol-4-il) butano- 1, 2, 3, 4- tetraol y (1R, 2S, 3R)-1-(2-Osoxasol-3-il)-1H-imidazol-4-iI) butano- 1, 2, 3, 4-tetraol anhidro cristalino.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7339808P | 2008-06-18 | 2008-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6341474A2 true CO6341474A2 (es) | 2011-11-21 |
Family
ID=41381634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11004598A CO6341474A2 (es) | 2008-06-18 | 2011-01-18 | Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US7998994B2 (es) |
EP (1) | EP2315765B1 (es) |
JP (1) | JP5550644B2 (es) |
KR (1) | KR20110036582A (es) |
CN (1) | CN102131803A (es) |
AR (1) | AR072153A1 (es) |
AU (1) | AU2009271408A1 (es) |
BR (1) | BRPI0914167A2 (es) |
CA (1) | CA2728094A1 (es) |
CL (1) | CL2009001436A1 (es) |
CO (1) | CO6341474A2 (es) |
DK (1) | DK2315765T3 (es) |
ES (1) | ES2401555T3 (es) |
IL (1) | IL209815A0 (es) |
MX (1) | MX2010013991A (es) |
PE (1) | PE20100085A1 (es) |
RU (1) | RU2011101535A (es) |
TW (1) | TW201004943A (es) |
UY (1) | UY31900A (es) |
WO (1) | WO2010008733A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201002698A (en) * | 2008-06-18 | 2010-01-16 | Lexicon Pharmaceuticals Inc | Methods of preparing imidazole-based bicyclic compounds |
EP2537831B1 (en) | 2010-02-18 | 2014-12-03 | Daiichi Sankyo Company, Limited | Imidazole derivative |
US9200309B2 (en) | 2010-06-28 | 2015-12-01 | Daiichi Sankyo Company, Limited | Method for screening for S1P lyase inhibitors using cultured cells |
DE102011103751A1 (de) | 2011-05-31 | 2012-12-06 | Heraeus Precious Metals Gmbh & Co. Kg | Kristallisierung von Epirubicinhydrochlorid |
US9120835B2 (en) | 2011-06-28 | 2015-09-01 | Daiichi Sankyo Company Limited | Phosphoric acid ester derivatives |
EP2545922A1 (en) | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567194A (en) * | 1983-03-10 | 1986-01-28 | The Coca-Cola Company | 2-Acylimidazole compounds, their synthesis and use as medicinal agents |
DE4430289A1 (de) * | 1993-09-04 | 1995-03-09 | Basf Ag | Verbessertes Verfahren zur Herstellung von Astaxanthin |
ZA974811B (en) | 1996-05-31 | 1997-12-30 | Univ Wollongong | Novel therapeutic compounds. |
JPH1149972A (ja) * | 1997-07-31 | 1999-02-23 | Jiyun Internatl:Kk | 殻廃棄物からアスタキサンチン及びキトーサンを同時に生成する方法 |
CN101232820B (zh) * | 2005-05-23 | 2012-09-05 | 法雷斯药品研究公司 | 直接溶解方法 |
EP1898928A2 (en) | 2005-06-28 | 2008-03-19 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
ITMI20052486A1 (it) * | 2005-12-23 | 2007-06-24 | Italiana Sint Spa | Procedimento di sintesi di intermedi per la preparazione di astaxantina |
US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
TW200848029A (en) * | 2007-03-01 | 2008-12-16 | Lexicon Pharmaceuticals Inc | Heterocyclic compounds, compositions comprising them and methods of their use |
TWI412362B (zh) * | 2007-04-12 | 2013-10-21 | Lexicon Pharmaceuticals Inc | (e)-1-(4-((1r,2s,3r)-1,2,3,4-四羥丁基)-1h-咪唑-2-基)乙酮肟的固體形式 |
TW201002698A (en) * | 2008-06-18 | 2010-01-16 | Lexicon Pharmaceuticals Inc | Methods of preparing imidazole-based bicyclic compounds |
AU2009282907A1 (en) * | 2008-08-22 | 2010-02-25 | Lexicon Pharmaceuticals, Inc. | Combinations comprising bicyclic S1P lyase inhibitors |
-
2009
- 2009-06-16 EP EP09744242A patent/EP2315765B1/en active Active
- 2009-06-16 MX MX2010013991A patent/MX2010013991A/es not_active Application Discontinuation
- 2009-06-16 PE PE2009000873A patent/PE20100085A1/es not_active Application Discontinuation
- 2009-06-16 US US12/485,444 patent/US7998994B2/en active Active
- 2009-06-16 JP JP2011514746A patent/JP5550644B2/ja not_active Expired - Fee Related
- 2009-06-16 ES ES09744242T patent/ES2401555T3/es active Active
- 2009-06-16 TW TW098120121A patent/TW201004943A/zh unknown
- 2009-06-16 DK DK09744242.0T patent/DK2315765T3/da active
- 2009-06-16 UY UY0001031900A patent/UY31900A/es not_active Application Discontinuation
- 2009-06-16 KR KR1020117001145A patent/KR20110036582A/ko not_active Application Discontinuation
- 2009-06-16 RU RU2011101535/04A patent/RU2011101535A/ru unknown
- 2009-06-16 BR BRPI0914167A patent/BRPI0914167A2/pt not_active IP Right Cessation
- 2009-06-16 AU AU2009271408A patent/AU2009271408A1/en not_active Abandoned
- 2009-06-16 CN CN2009801233805A patent/CN102131803A/zh active Pending
- 2009-06-16 AR ARP090102172A patent/AR072153A1/es not_active Application Discontinuation
- 2009-06-16 WO PCT/US2009/047488 patent/WO2010008733A2/en active Application Filing
- 2009-06-16 CA CA2728094A patent/CA2728094A1/en not_active Abandoned
- 2009-06-17 CL CL2009001436A patent/CL2009001436A1/es unknown
-
2010
- 2010-12-07 IL IL209815A patent/IL209815A0/en unknown
-
2011
- 2011-01-18 CO CO11004598A patent/CO6341474A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090318516A1 (en) | 2009-12-24 |
CN102131803A (zh) | 2011-07-20 |
DK2315765T3 (da) | 2013-03-25 |
UY31900A (es) | 2010-01-29 |
CA2728094A1 (en) | 2010-01-21 |
WO2010008733A2 (en) | 2010-01-21 |
WO2010008733A3 (en) | 2010-03-25 |
AU2009271408A1 (en) | 2010-01-21 |
JP5550644B2 (ja) | 2014-07-16 |
US7998994B2 (en) | 2011-08-16 |
RU2011101535A (ru) | 2012-07-27 |
TW201004943A (en) | 2010-02-01 |
EP2315765B1 (en) | 2012-12-19 |
ES2401555T3 (es) | 2013-04-22 |
IL209815A0 (en) | 2011-02-28 |
BRPI0914167A2 (pt) | 2015-10-20 |
KR20110036582A (ko) | 2011-04-07 |
EP2315765A2 (en) | 2011-05-04 |
JP2011524915A (ja) | 2011-09-08 |
AR072153A1 (es) | 2010-08-11 |
CL2009001436A1 (es) | 2010-10-01 |
MX2010013991A (es) | 2011-01-14 |
PE20100085A1 (es) | 2010-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118454T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
CU23614B7 (es) | Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
CR20150625A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
CU20060037A7 (es) | Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
CU23615B7 (es) | Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
CL2009000923A1 (es) | Compuestos derivados de 1-(aminoacetil)-n-(1-cicloalquil)pirrolidina-2-carboxamida sustituidas; composicion farmaceutica; utiles para tratar la hepatitis c. | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
ECSP10010722A (es) | Compuestos orgánicos | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
CR10955A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
CO6341474A2 (es) | Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso | |
GT200900192A (es) | Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).- | |
EA201401193A1 (ru) | Триарильные соединения и композиции, их содержащие | |
CU20110113A7 (es) | Lactamas como inhibidores beta secretasa | |
ATE509931T1 (de) | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür | |
EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
CR10960A (es) | Nuevo procedimiento de sintesis de la agomelatina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |